All In Biotech

Drug Trial Radar · NCT02412787

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment

Last checked: Nov 20, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

56

Actual

Start

Apr 14, 2015

Primary completion

Apr 18, 2024

Study completion Apr 18, 2024

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Apr 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This extension study will allow participants that completed Study HGT-HIT-094 to continue receiving Elaprase treatment in conjunction with idursulfase IT or to continue receiving Elaprase treatment and begin concurrent IT treatment for those that did not receive idursulfase IT treatment in Study HGT-HIT-094.

Conditions

  • Hunter Syndrome

Interventions

  • Idursulfase-ITDrug

    Participants received 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who were younger than 3 years of age received an adjusted dose of 7.5 mg (\>8 months to 30 months of age) and 10 mg (\>30 months to 3 years of age).

  • ElapraseDrug

    Participants received intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to 9 years
  2. Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Up to 9 years
  3. Number of Participants With Clinically Significant Changes in Laboratory ParametersTime frame: Up to 9 years
  4. Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) FindingsTime frame: Up to 9 years
  5. Maximum Observed Serum Concentration (Cmax) of IdursulfaseTime frame: Predose and at 30 min, 60 min, 120 min, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 30 hours and 36 hours post-dose at Week 100 in relation to HGT-HIT-094 (Week 48 of this study)
  6. Percent Change From Baseline in the Concentration of Glycosaminoglycan (GAG) in CSF at Month 67Time frame: For participants who began IT treatment in HGT-HIT-094: From Baseline of HGT-HIT-094 up to Month 67 in relation to HGT-HIT-094; For participants who began IT treatment in this study: From Baseline of this study up to Month 55 of this study.
  7. Percent Change From Baseline in the Concentration of GAG in Urine at Month 67Time frame: For participants who began IT treatment in HGT-HIT-094: From Baseline of HGT-HIT-094 up to Month 67 in relation to HGT-HIT-094; For participants who began IT treatment in this study: From Baseline of this study up to Month 55 of this study.
  8. Number of Participants Who Reported Positive for Anti-idursulfase Antibodies in CSFTime frame: Up to 9 years
  9. Number of Participants Who Reported Positive for Anti-idursulfase Antibodies in SerumTime frame: Up to 9 years

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Children's Hospital and Research Center at Oakland

    Oakland, California

  • Ann & Robert H Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of North Carolina

    Chapel Hill, North Carolina

  • Women's and Children's Hospital

    Adelaide, Australia

  • The Hospital for Sick Children

    Toronto, Ontario, Canada

  • Hôpital Femme Mère Enfants

    Bron, France

  • Instituto Nacional de Pediatría

    Coyoacán, Mexico City, Mexico

  • Hospital Infantil Universitario Niño Jesus

    Madrid, Spain

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.